Product
dupilumab
Aliases
Dupixent, Dupixent®, • DUPIXENT, DUPIXENT® (5 other aliases)
14 clinical trials
11 indications
Indication
Allergic Bronchopulmonary AspergillosisIndication
Atopic Hand and Foot DermatitisIndication
Food AllergyIndication
Bullous PemphigoidIndication
Atopic DermatitisIndication
ConjunctivitisIndication
Adverse Pregnancy OutcomesIndication
AsthmaIndication
Chronic RhinosinusitisIndication
EosinophiliaIndication
Hypereosinophilic SyndromeClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary AspergillosisStatus: Completed, Estimated PCD: 2023-07-27
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot DermatitisStatus: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Phase 1 Dose-Escalation Study in Adults With Severe IgE-Mediated Food Allergy, to Assess the Safety, Tolerability, and Pharmacodynamic Effects of Short-Term Linvoseltamab Treatment, A BCMAxCD3 Bispecific Antibody to Induce T-Cell Killing of IgE Producing Plasma Cells, on Top of Chronic Dupilumab Treatment, to Prevent the Formation of New IgE Producing Plasma CellsStatus: Recruiting, Estimated PCD: 2026-04-24
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous PemphigoidStatus: Active (not recruiting), Estimated PCD: 2024-11-11
Clinical trial
A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants (≥6 to <15 Years of Age) With Moderate-to-severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2026-05-29
Clinical trial
Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2023-03-10
Clinical trial
Dupilumab and Pregnancy Outcomes: A Retrospective Cohort Study Using Administrative Healthcare Databases (Dupi PODS)Status: Recruiting, Estimated PCD: 2027-07-21
Clinical trial
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic DermatitisStatus: Completed, Estimated PCD: 2023-03-29
Clinical trial
Post-Authorization Safety Study to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy in North AmericaStatus: Recruiting, Estimated PCD: 2026-07-09
Clinical trial
An Open-Label, Expanded Access Program of Dupilumab in Adult Patients With Bullous PemphigoidStatus:
Clinical trial
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP): a Randomized Double Blind Placebo Controlled Phase II StudyStatus: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients With Moderate-to-Severe AsthmaStatus: Completed, Estimated PCD: 2023-07-15
Clinical trial
Treatment of Rhinosinusitis With Nasal Polyposis With Dupilumab and Mepolizumab: A Randomized, Multi-centre, Head-to-head Comparison in Real-world Danish PatientsStatus: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsStatus: Not yet recruiting, Estimated PCD: 2026-12-30